Literature DB >> 26089220

ACR Appropriateness Criteria® Ductal Carcinoma in Situ.

Seth A Kaufman, Eleanor E R Harris, Lisa Bailey, Manjeet Chadha, Sharon C Dutton, Gary M Freedman, Sharad Goyal, Michele Y Halyard, Kathleen C Horst, Kristina L M Novick, Catherine C Park, W Warren Suh, Deborah Toppmeyer, Jennifer Zook, Bruce G Haffty.   

Abstract

Ductal carcinoma in situ (DCIS) is a breast neoplasm with potential for progression to invasive cancer. Management commonly involves excision, radiotherapy, and hormonal therapy. Surgical assessment of regional lymph nodes is rarely indicated except in cases of microinvasion or mastectomy. Radiotherapy is employed for local control in breast conservation, although it may be omitted for select low-risk situations. Several radiotherapy techniques exist beyond standard whole-breast irradiation (ie, partial-breast irradiation [PBI], hypofractionated whole-breast radiation); evidence for these is evolving. We present an update of the American College of Radiology (ACR) Appropriateness Criteria® for the management of DCIS. The ACR Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions, which are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi technique) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26089220

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  10 in total

1.  Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.

Authors:  Charles Bechert; Jee-Yeon Kim; Trine Tramm; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-09-23       Impact factor: 4.064

2.  When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions.

Authors:  Tomás Cortadellas; Paula Argacha; Juan Acosta; Judith Jurado; Ricardo Peiró; Margarita Gomez; Xavier Gonzalez-Farré; Milagros Martinez; Miguel Luna; Vicente Peg; Antonio Gil-Moreno; Manel Xiberta
Journal:  Breast Care (Basel)       Date:  2021-03-30       Impact factor: 2.860

3.  Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.

Authors:  Danielle Rodin; Rinku Sutradhar; Sharon Nofech-Mozes; Sumei Gu; Neil Faught; Ezra Hahn; Cindy Fong; Sabina Trebinjac; Lawrence Paszat; Eileen Rakovitch
Journal:  Breast Cancer Res Treat       Date:  2022-01-27       Impact factor: 4.872

4.  Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

Authors:  L M van Roozendaal; B Goorts; M Klinkert; K B M I Keymeulen; B De Vries; L J A Strobbe; C A P Wauters; Y E van Riet; E Degreef; E J T Rutgers; J Wesseling; M L Smidt
Journal:  Breast Cancer Res Treat       Date:  2016-04-15       Impact factor: 4.872

Review 5.  Evaluation of guidelines regarding surgical treatment of breast cancer using the AGREE Instrument: a systematic review.

Authors:  Xin Lei; Fengtao Liu; Shuying Luo; Ya Sun; Liling Zhu; Fengxi Su; Kai Chen; Shunrong Li
Journal:  BMJ Open       Date:  2017-11-14       Impact factor: 2.692

6.  Clinical and imaging characteristics of breast ductal carcinoma in situ with microinvasion.

Authors:  Sijia Han; Fang Qiu; Ye Han; Yongqing Xu; Jianqiao Yin; Fei Xing; Xiaobo Bian; Guijin He
Journal:  J Appl Clin Med Phys       Date:  2020-12-17       Impact factor: 2.102

7.  Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary?

Authors:  Robbert J H van Leeuwen; Birgitta Kortmann; Herman Rijna
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860

8.  Ductal Carcinoma in situ: Underestimation of Percutaneous Biopsy and Positivity of Sentinel Lymph Node Biopsy in a Brazilian Public Hospital.

Authors:  Rafael da Silva Sá; Angela Flávia Logullo; Simone Elias; Gil Facina; Vanessa Monteiro Sanvido; Afonso Celso Pinto Nazário
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-06-21

9.  Breast segmentectomy with rotation mammoplasty as an oncoplastic approach to extensive ductal carcinoma in situ.

Authors:  Bartlomiej Szynglarewicz; Adam Maciejczyk; Jozef Forgacz; Rafal Matkowski
Journal:  World J Surg Oncol       Date:  2016-03-09       Impact factor: 2.754

10.  Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study.

Authors:  Serena Bertozzi; Carla Cedolini; Ambrogio P Londero; Barbara Baita; Francesco Giacomuzzi; Decio Capobianco; Marta Tortelli; Alessandro Uzzau; Laura Mariuzzi; Andrea Risaliti
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.